LSD as a Treatment for Anxiety Disorders: New Evidence of Efficacy

Wednesday, May 11, 2022 10:05 AM to 10:25 AM · 20 min. (Europe/London)
Sainsbury Wing Theatre
Research Presentation
Data & AnalysisDrug DevelopmentLSDMental HealthResearch

Information

LSD was extensively investigated in humans in the 1950s and 1960s, showing particular effect in mitigating anxiety in patients with cancer. Dr. Holze and Dr. Liechti will present preliminary data from a Phase II study to test the efficacy of LSD in patients with anxiety, both with and without life-threatening diseases.

Audience Q&A
No
MindMedMindMed is a clinical-stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems. MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.

Registered attendees

Alexandra Plesner
Alexandra Plesner
Strategic Designer and ResearchercreATP
Dan Karlin
Dan Karlin
CMOMindMed
Ken Belotsky
Ken Belotsky
PartnerNegev Capital Fund

Log in